A Clinician's guide to vitamin D supplementation for patients with cystic fibrosis
- PMID: 34815946
- PMCID: PMC8593649
- DOI: 10.1016/j.jcte.2021.100273
A Clinician's guide to vitamin D supplementation for patients with cystic fibrosis
Abstract
Vitamin D deficiency is common in the general population, and even more so in patients with cystic fibrosis. Deficiency is exacerbated in cystic fibrosis patients because of a myriad of causes including malabsorption, decreased fat mass, reduced 25-hydroxylation of vitamin D, reduced exposure to sunlight, decreased vitamin D binding protein, and exposure to drugs that increase catabolism. In turn, vitamin D deficiency can contribute to poor bone health. Additionally, it may contribute to pulmonary decline in the form of worsening pulmonary function, increased colonization with pathogens, and increased pulmonary exacerbation. Because vitamin D deficiency is correlated with negative clinical effects in multiple organ systems of patients with cystic fibrosis, it is important to screen for and treat deficiency in these patients. The Cystic Fibrosis Foundation has issued guidelines for the treatment of vitamin D deficiency, targeting serum levels of 25-hydroxyvitamin D of at least 30 ng/ml. The guidelines offer age-specific escalating dose regimens depending on serum vitamin D levels, with monitoring at 12- week intervals after changing therapy. They address the literature on alternative vitamin D sources, such as UV lamps, ideal formulations (cholecalciferol in preference to ergocalciferol), and optimal vehicles of administration. Despite these detailed recommendations, most centers are still unable to achieve in-target serum vitamin D levels for many of their patients. Future research examining ideal treatment regimens to achieve serum targets and maximize clinical effects are needed. Moreover, it is unknown whether vitamin D sufficiency will be easier to achieve on new triple therapy cystic fibrosis drug combinations, and how these drugs will contribute to vitamin D-related clinical outcomes.
Keywords: 25(OH)D, 25-hydroxyvitamin D; BMD, bone mineral density; CF, cystic fibrosis; CFRD, cystic fibrosis-related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; Cholecalciferol; Cystic fibrosis; D2, ergocalciferol; D3, cholecalciferol; Metabolism; NTM, nontuberculous mycobacteria; PTH, parathyroid hormone; RTC, randomized control trial; Review; Supplementation; Treatment; Vitamin D.
© 2021 The Author(s).
Similar articles
-
Vitamin D deficiency and its treatment in cystic fibrosis.J Cyst Fibros. 2019 Oct;18 Suppl 2:S66-S73. doi: 10.1016/j.jcf.2019.08.022. J Cyst Fibros. 2019. PMID: 31679731 Review.
-
A randomized controlled trial of vitamin D replacement strategies in pediatric CF patients.J Cyst Fibros. 2016 Mar;15(2):234-41. doi: 10.1016/j.jcf.2015.07.004. Epub 2015 Jul 23. J Cyst Fibros. 2016. PMID: 26211605 Clinical Trial.
-
Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D3 administration.Metabolism. 2017 May;70:31-41. doi: 10.1016/j.metabol.2017.02.006. Epub 2017 Feb 11. Metabolism. 2017. PMID: 28403943 Free PMC article. Clinical Trial.
-
Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis.JPEN J Parenter Enteral Nutr. 2017 Aug;41(6):952-958. doi: 10.1177/0148607116629673. Epub 2016 Feb 22. JPEN J Parenter Enteral Nutr. 2017. PMID: 26903303 Free PMC article. Clinical Trial.
-
Management of osteoporosis in adults with cystic fibrosis.Drugs. 2004;64(2):133-47. doi: 10.2165/00003495-200464020-00002. Drugs. 2004. PMID: 14717616 Review.
Cited by
-
Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin D3) (Pre-D trial) in adults with cystic fibrosis.Contemp Clin Trials Commun. 2024 Feb 18;38:101278. doi: 10.1016/j.conctc.2024.101278. eCollection 2024 Apr. Contemp Clin Trials Commun. 2024. PMID: 38435430 Free PMC article.
-
Vitamin D deficiency in patients with cystic fibrosis: a systematic review and meta-analysis.J Health Popul Nutr. 2024 Jan 17;43(1):11. doi: 10.1186/s41043-024-00499-2. J Health Popul Nutr. 2024. PMID: 38233891 Free PMC article.
-
The Relation between Vitamin D Level and Lung Clearance Index in Cystic Fibrosis-A Pilot Study.Children (Basel). 2022 Mar 1;9(3):329. doi: 10.3390/children9030329. Children (Basel). 2022. PMID: 35327701 Free PMC article.
-
Calcium, Phosphorus, and Vitamin D Levels in a Series of Cystic Fibrosis Patients: A Cross-Sectional Study.Int J Mol Sci. 2024 Feb 5;25(3):1900. doi: 10.3390/ijms25031900. Int J Mol Sci. 2024. PMID: 38339178 Free PMC article.
-
Vitamin D for glycemic control following an acute pulmonary exacerbation: A secondary analysis of a multicenter, double-blind, randomized, placebo-controlled trial in adults with cystic fibrosis.medRxiv [Preprint]. 2024 Mar 10:2024.01.04.24300862. doi: 10.1101/2024.01.04.24300862. medRxiv. 2024. PMID: 38343807 Free PMC article. Preprint.
References
-
- Rovner A.J., et al. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. The American Journal of Clinical Nutrition. 2007;86(6):1694–1699. - PubMed
-
- Abu-Fraiha Y., et al. Increasing vitamin D serum levels is associated with reduced pulmonary exacerbations in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2019;68(1):110–115. - PubMed
-
- Holick M.F. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281. - PubMed
-
- Daley T., Hughan K., Rayas M., Kelly A., Tangpricha V. Vitamin D deficiency and its treatment in cystic fibrosis. J Cyst Fibros. 2019;18:S66–S73. - PubMed
LinkOut - more resources
Full Text Sources